Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Tesamorelin · dosing reference

What dose information exists for Tesamorelin?

An FDA-approved growth hormone-releasing factor analogue specifically indicated for HIV-associated lipodystrophy. Other cosmetic, bodybuilding, or anti-aging uses discussed online are unapproved.

Official product dosing

Official

Approved indication, route, dose, frequency and titration, sourced only from the FDA label, DailyMed or the manufacturer's prescribing information.

Official labelEGRIFTA SV (tesamorelin) for injection
Approved indication
Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Route
Subcutaneous injection once daily
Dose
1.4 mg (EGRIFTA SV) or 2.0 mg (original EGRIFTA) once daily
Frequency
Once daily into abdomen
  • EGRIFTA SV is formulated at 2 mg per vial reconstituted to 1.4 mg/0.35 mL.
  • Label explicitly states it is not indicated for general weight loss.

Published human study doses

Human study

Intervention parameters reported in individual published human studies. Each study stays separate; parameters are never aggregated across studies.

Human studyFalutz et al., NEJM (2007)
Population
412 HIV-infected patients with excess abdominal fat accumulation
Route
Subcutaneous
Dose as published
2 mg subcutaneous once daily vs placebo for 26 weeks
Frequency
Once daily
Duration
26 weeks
Endpoint
Visceral adipose tissue decreased by 15.2% in tesamorelin group vs increase of 2.1% in placebo group (p < 0.001); IGF-1 increased by 81.0%.

Community-reported ranges

Community

What people report discussing or doing in forums, on Reddit and in videos. Included only to show demand and reported practice — never as clinical evidence.

Community reportedmoderate discussion volume

Community discussions typically mirror the 1–2 mg daily clinical dose, often cycling 5 days on / 2 days off for visceral fat or body composition.

  • Unapproved for general body composition. IGF-1 levels should be monitored under clinical care due to proliferative risks.
Reddit r/Peptides · Bodybuilding forums · Last checked 22 September 2026

Community reports describe what people say they are doing. They are not equivalent to clinical evidence, and discussion volume says nothing about whether a practice is safe, effective or even real.

Why community reports are shown at all

People search for dose information before they search for anything else in this sector. Where discussion is widespread, pretending it does not exist helps nobody. Therapept reports the discussion — its rough shape, how common it is, and where it happens — while keeping it visibly separate from every other kind of source. Community reports describe what people say they are doing. They are not equivalent to clinical evidence.

Last reviewed 22 September 2026 · Compiled by Therapept Editorial · How these records are built